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Abstract
The (pro)renin receptor [(P)RR] binds to renin and its precursor prorenin to activate the tis-
sue renin-angiotensin system. It is cleaved to generate soluble (P)RR and M8–9, a residual
hydrophobic truncated protein. The (pro)renin receptor also functions as an intracellular
accessory protein of vacuolar-type H+-ATPase, which plays an essential role in controlling
the intracellular vesicular acid environment. Thus, in the kidney, (P)RR may play a role in
transporting H+ to urine in the collecting duct. Although blood soluble (P)RR has been recog-
nized as a biomarker reflecting the status of the tissue renin-angiotensin system and/or tis-
sue (P)RR, the significance of urinary soluble (P)RR excretion has not been determined.
Therefore, this study aimed to investigate the characteristics of urinary soluble (P)RR excre-
tion. Urinary soluble (P)RR excretion was measured, and its association with background
factors was investigated in 441 patients. Relationships between changes in urine pH due to
vitamin C treatment, which reduce urine pH, and urinary soluble (P)RR excretion were
investigated in 10 healthy volunteers. Urinary soluble (P)RR excretion was 1.46 (0.44–2.92)
ng/gCre. Urine pH showed a significantly positive association with urinary soluble (P)RR
excretion, independent of other factors. Changes in urine pH and urinary soluble (P)RR
excretion due to vitamin C treatment were significantly and positively correlated (ρ = 0.8182,
p = 0.0038). These data showed an association between urinary soluble (P)RR excretion
and urine pH in humans, suggesting that (P)RR in the kidney might play a role in urine pH
regulation.
Introduction
The (pro)renin receptor [(P)RR], which consists of 350 amino acids with a single transmem-
brane domain and binds to renin and prorenin, is widely expressed in various tissues, includ-
ing the heart, brain, and kidney [1]. The binding of prorenin to the extracellular domain of the
(P)RR induces non-proteolytic renin activation [2], which accelerates the conversion of angio-
tensinogen to angiotensin. This process plays a key role in regulating the tissue renin-angio-
tensin system (RAS) [1]. The (P)RR also stimulates its own intracellular signal transduction
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pathways, such as the mitogen-activated protein kinase (MAPK) pathways, independent of the
RAS [1]. (P)RR also functions as an accessory protein of vacuolar H+-ATPase (V-ATPase),
which is an ATP-dependent proton pump that plays an important role in the transportation of
protons across plasma membranes, acidifies the intracellular compartments [3], and plays a
role in secretion and membrane fusion independent of acidification [4–7]. The (P)RR also
serves as an adaptor protein between the V-ATPase and Wnt receptor complex [8], which is
involved in virtually every aspect of embryonic development and in homeostatic self-renewal
[9]. In addition, binding of (P)RR to pyruvate dehydrogenase E1 β-subunit (PDHB) prevents
PDHB phosphorylation and maintains aerobic glucose metabolism [10]. Therefore, (P)RR is
considered a multifunctional protein that exhibits complex structure and functionality [11].
(P)RR is cleaved to be soluble (P)RR [s(P)RR], which is secreted into the extracellular space
and is ultimately found in both blood and urine [12, 13]. Blood s(P)RR may serve as a bio-
marker that reflects the expression levels of tissue RAS and/or tissue (P)RR [14, 15]. However,
the significance of urinary s(P)RR excretion in humans remains unclear. Therefore, the pres-
ent study investigated the characteristics of urinary s(P)RR excretion in humans.
Materials and methods
Study 1
This study enrolled 441 consecutive patients who visited the Department of Endocrinology
and Hypertension at the Tokyo Women’s Medical University Hospital between September
2013 and February 2016. Power analyses could not be performed because no preliminary data
on urinary s(P)RR excretion in humans are available. This study was conducted according to
the principles of the 1975 Declaration of Helsinki, as revised in 2013. Patients who had suffered
from acute myocardial infarction or stroke in the previous 6 months, pregnant women, and
those with apparent peripheral vascular or malignant disease were excluded. All participants
were enrolled after obtaining written informed consent and approval from the ethical commit-
tee of Tokyo Women’s Medical University (approval #: 2303).
Background factors. At enrollment, information was collected on sex, age, hypertension,
body mass index (BMI), and waist circumference (WC). Hypertension was diagnosed when
the patients were already under treatment with antihypertensive agents or met the criteria of
the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH
2019) [16]. WC was measured at the level of the umbilicus while the patient was standing and
after exhaling.
Visceral fat area. Visceral fat area (VFA) was estimated by the bioelectrical impedance
analysis method using HDS-2000 DUALSCAN1 (Omron Healthcare Co., Kyoto, Japan) in
the morning after a 12-h fast, as previously described [17].
Blood pressure and pulse rate. Office blood pressure (BP) and pulse rate (PR) were mea-
sured with the patient in a sitting position after resting for at least 5 min using an automated
sphygmomanometer.
Urinary examinations. Spot urine samples were obtained, and the pH and concentrations
of albumin (Alb) and creatinine (Cre) were quantified using standardized assessment methods
at our clinical laboratory. Urinary serum soluble s(P)RR concentrations were measured using
an enzyme-linked immunosorbent assay kit (Takara Bio, Otsu City, Japan), consisting of a
solid-phase sandwich enzyme-linked immunosorbent assay with a highly specific antibody
[18]. For this measurement, 100 μL of addition agent (0.25% casein-Na, 5% BSA, 0.05% NaN3)
was added to 10 ml of spot urine to prevent adsorption to the test tube wall. Excretions of Alb
or s(P)RR were determined by dividing these values by the Cre concentrations.
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Blood examinations. Blood samples were collected while patients were in the sitting posi-
tion after at least 15 min of rest and an overnight fast. Hemoglobin (Hb), uric acid, creatinine,
calcium (Ca), inorganic phosphorus (IP), albumin, intact parathyroid hormone (i-PTH),
blood sugar (BS), insulin, hemoglobin A1c (HbA1c), low-density lipoprotein (LDL)-choles-
terol, high-density lipoprotein (HDL)-cholesterol, triglyceride (TG), high-sensitivity C-reac-
tive protein (hsCRP), and brain natriuretic peptide (BNP) levels were measured using
standard laboratory methods at our clinical laboratory. The corrected Ca was calculated using
the formula: corrected Ca = Ca–Alb + 4.0 (mg/dl (if Alb < 4.0) [19]. The estimated glomerular
filtration rate (eGFR) was calculated using the following equation:
eGFR ðmL=min=1:73 m2Þ ¼ 194� Cre  1:094 � age  0:287 ð�0:739; if femaleÞ
[20]. Serum soluble s(P)RR concentrations were measured using an enzyme-linked immuno-
sorbent assay kit (Takara Bio, Otsu City, Japan) [18].
Western blot analysis for s(P)RR using urine samples. Urine was obtained from five
patients. Urine, Chinese hamster ovary cells transfected with cDNA for (P)RR as a positive
control, and an electrolyte solution (dialysate: LYMPAC TA1; Nipro Corp, Osaka, Japan) as a
negative control were lysed using a solution containing 2% SDS, 10% glycerol, 50 mM Tris-
HCl (pH 6.8), and 100 mM dithiothreitol, boiled, and subjected to western blot analysis using
93A1B, an anti-(P)RR antibody, supplied by the s(P)RR ELISA kit. The reactivity of the anti-
bodies was assessed by immunoprecipitation using western blotting. Urine samples and posi-
tive and negative control samples were incubated with 93A1B, and then Protein G Sepharose
(GE Healthcare Japan, Hino City, Japan) was added. After further incubation, the samples
were centrifuged, and the resulting pellets were washed three times. The pellets were subse-
quently lysed, and western blot analysis was performed using 93A1B.
Study protocol. The relationship between background factors, VFA, office BP and PR,
urinary and blood data, and urinary s(P)RR excretion or serum s(P)RR concentration were
examined by single or multiple regression analyses.
Statistical analyses. All data are expressed as the mean ± standard deviation or median
value (interquartile range). The Mann-Whitney U test was used to compare the two groups. A
single correlation analysis was performed using Spearman’s rank correlation to determine the
association between background factors, VFA, office BP and PR, urinary and blood data, and
urinary s(P)RR excretion or serum s(P)RR concentration. Multiple regression analysis was
used to identify the determinants of urinary s(P)RR excretion or serum s(P)RR concentration
by forward stepwise analysis. The level of significance was set at P < 0.05. All statistical analy-
ses were performed using JMP Pro version 15 (SAS Institute Inc., Cary, NC, USA).
Study 2
Ten male volunteers without any past medical history were recruited between February and
March 2017 among students at Keio University (Tokyo, Japan) and were enrolled after obtain-
ing written informed consent. At enrollment, BP and PR, fasting BS, HbA1c, and serum creati-
nine levels were measured using the same methods as in Study 1. In addition, a qualitative
urine test was performed at enrollment. They were treated with 600 mg of ascorbic acid cal-
cium pantothenate, a vitamin C tablet, thrice daily for 14 days to decrease the urine pH. This
study was conducted according to the principles of the 1975 Declaration of Helsinki, as revised
in 2013, and was approved by the ethical committee of Tokyo Women’s Medical University
(approval #: 170308).
Study protocol. Urine pH and urinary s(P)RR excretion were measured in spot urine
samples obtained before and after treatment using the same methods as in Study 1. The
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relationship between changes in urine pH and urinary s(P)RR excretion due to vitamin C
treatment was investigated.
Statistical analyses. All data are expressed as means ± standard deviations or as medians
(interquartile range). Wilcoxon signed-rank tests were applied to determine the difference in
urine pH or urinary s(P)RR expression before and after treatment. Single correlation analysis
was performed using Spearman’s rank correlation to determine the association between
changes in urine pH or urinary s(P)RR excretion due to the treatment. The level of significance
was set at P < 0.05. All statistical analyses were performed using JMP Pro version 15 (SAS
Institute Inc., Cary, NC, USA).
Table 1. Characteristics of the study subjects.
Sex (male/female) 267/174
Age (y.o.) 54 (44–66)
Hypertension (yes/no) 286/155
BMI (kg/m2) 23.8 (21.5–26.4)
Waist circumference (cm) 87.2 (80.0–95.0)
Visceral fat area (cm2) 73.0 (48.3–105.8)
Office BP and pulse rate
Systolic BP (mmHg) 131±20
Diastolic BP (mmHg) 80±15
Pulse rate (beats/min) 69 (61–77)
Urine tests
pH 6.321 (5.800–6.820)
Log pH 1.84 (1.76–1.92)
Creatinine (mg/dl) 88 (55–135)
Albumin (mg/g creatinine) 7.9 (4.6–20.0)
s(P)RR/creatinine (ng/g creatinine) 1.46 (0.44–2.92)
Log s(P)RR/creatinine 0.38 (-0.82–1.07)
Blood tests
Hemoglobin (g/dl) 13.5±1.4
Uric acid (mg/dl) 5.1 (4.3–6.0)
Creatinine (mg/dl) 0.69 (0.59–0.83)
eGFR (ml/min/1.73 m2) 77.0 (65.5–88.8)
Corrected calcium (mg/dl) 9.0 (8.8–9.2)
Inorganic phosphorus (mg/dl) 3.5 (3.1–3.9)
Albumin (g/dl) 4.2 (3.9–4.4)
Intact–PTH (pg/ml) 52 (40–65)
Blood sugar (mg/dl) 93 (87–102)
Insulin (nmol) 4.9 (3.3–8.0)
Hemoglobin A1c (%) 5.7 (5.5–6.0)
LDL-cholesterol (mg/dl) 118 (97–140)
HDL-cholesterol (mg/dl) 58 (48–70)
Triglyceride (mg/dl) 106 (76–147)
hs CRP (ng/ml) 476 (186–1250)
s(P)RR (ng/ml) 23.8 (21.0–27.2)
Data are presented as the means ± standard deviations and medians (interquartile range). Abbreviations: BMI, body
mass index; BP, blood pressure; s(P)RR, soluble (pro)renin receptor; eGFR, estimated glomerular filtration rate;
PTH, parathyroid hormone; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hsCRP, high-sensitivity
C-reactive protein; BNP, brain natriuretic peptide.
https://doi.org/10.1371/journal.pone.0254688.t001
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Results
Study 1
Characteristics of the study participants. A total of 441 patients (133 patients with essen-
tial hypertension, 143 patients with secondary hypertension, and 165 patients with other endo-
crine or metabolic disorders) were enrolled in this study. Table 1 shows the background
factors, VFA, office BP and PR, and urinary and blood data. The median urinary s(P)RR excre-
tion level was 1.46 (interquartile range: 0.44–2.92) ng/gCre and the median serum s(P)RR level
was 23.8 (interquartile range: 21.0–27.2) ng/gCre.
Detection of urinary s(P)RR excretion. The results of the immunoprecipitation western
blotting are shown in Fig 1. In all five of the urinary s(P)RR samples, a band indicating s(P)RR
was detected, confirming that s(P)RR was excreted into the urine.
Single correlation analysis with urinary s(P)RR excretion levels. Urinary s(P)RR excre-
tion was significantly higher in women (1.73, 0.60–3.33 ng/gCre) than in men (1.13, 0.22–2.22
ng/gCre) (P< 0.0001), which was considered to be due to significantly lower urinary Cre con-
centration in women (73, 46–10 mg/dl) compared to men (109, 77–159 mg/dl) (P < 0.0001),
particularly since the urinary s(P)RR concentrations were similar between women (10.4, 5.22–
18.66 ng/ml) and men (9.75, 2.87–21.1 ng/ml). Urinary s(P)RR excretion was significantly
lower in patients with BMI� 25 kg/m2 than in those with BMI < 25 kg/m2 (Fig 2a), while it
was not significantly different between those with normotensive and hypertensive patients
(Fig 2b). In the single correlation analyses, urine pH, eGFR, and HDL-cholesterol were signifi-
cantly and positively correlated with urinary s(P)RR excretion and log urine pH was signifi-
cantly as well as positively correlated with log urinary s(P)RR excretion (Table 2, Fig 3a and
3b). BMI, WC, VFA, uric acid, Cre, IP, BS, insulin, TG, hs-CRP, and serum s(P)RR levels
were significantly and negatively correlated with urinary s(P)RR excretion levels (Table 2,
Fig 1. Western blotting and immunoprecipitation analysis. Identification of urinary soluble (Pro) renin receptor in five patients (A, B, C, D, and
E). s(P)RR, soluble (Pro) renin receptor.
https://doi.org/10.1371/journal.pone.0254688.g001
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Fig 3a–3c). Urine pH showed the strongest relationship with urinary s(P)RR excretion levels
(Table 2).
Multiple regression analyses with urinary s(P)RR excretion. To compare the strength of
the relationship between urinary s(P)RR excretion level and the possible predictor variables,
multiple regression analysis testing with urine pH, uric acid, eGFR, TG, serum s(P)RR
Fig 2. Comparisons of urinary s(P)RR excretion between patients with and without obesity (a) and those with and
without hypertension (b). s(P)RR, soluble (pro)renin receptor; BMI, body mass index.
https://doi.org/10.1371/journal.pone.0254688.g002
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concentration, and VFA as independent variables was performed. Urine pH and VFA were
selected as the independent variables. Urine pH was significantly and positively associated and
VFA was significantly and negatively associated with urinary s(P)RR excretion. The associa-
tion was stronger in urine pH than in VFA, indicating that urine pH has the strongest relation-
ship with urinary s(P)RR excretion, independent of other factors (Table 3a).
Single correlation analysis with serum s(P)RR levels. Because serum s(P)RR showed a
significant negative relationship with urinary s(P)RR excretion level, we also investigated the
relationships between serum s(P)RR concentration and background factors. Serum s(P)RR
concentration was significantly higher in patients with a BMI� 25 kg/m2 compared to those
with a BMI < 25 kg/m2 (Fig 4a); however, it was not significantly different between normoten-
sive and hypertensive patients (Fig 4b). Single correlation analyses showed that age, BMI, WC,
VFA, urine Alb excretion, Hb, uric acid, Cre, Ca, BS, insulin, HbA1c, TG, and hsCRP were sig-
nificantly and positively correlated, and urine pH, eGFR, and HDL-cholesterol were signifi-
cantly and negatively correlated with serum s(P)RR concentration (Table 4, Fig 5a–5c).




Waist circumference -0.266 <0.001
Visceral fat area -0.256 <0.001
Office BP and pulse rate
Systolic BP -0.006 0.900
Diastolic BP 0.015 0.768






Uric acid -0.267 <0.001
Creatinine -0.267 <0.001
eGFR 0.168 <0.001
Corrected calcium -0.087 0.103
Inorganic phosphorus -0.108 0.040
Albumin 0.055 0.287
Intact-PTH 0.042 0.541
Blood sugar -0.135 0.005
Insulin -0.255 <0.001




hs CRP -0.137 0.005
s(P)RR -0.162 0.001
Abbreviations: BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; PTH,
parathyroid hormone; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-
reactive protein; BNP, brain natriuretic peptide; s(P)RR, soluble (pro)renin receptor.
https://doi.org/10.1371/journal.pone.0254688.t002
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Fig 3. Scattergrams showing relationship between log urine pH (a) and log urinary s(P)RR excretion (a) and
HDL-cholesterol (b) or visceral fat area (c) and urinary s(P)RR excretion. s(P)RR, soluble (pro)renin receptor;
HDL, high-density lipoprotein.
https://doi.org/10.1371/journal.pone.0254688.g003
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Multiple regression analyses with serum s(P)RR levels. Several studies have indicated
that blood s(P)RR levels are significantly and negatively associated with eGFR [15, 21, 22].
Data from the present study confirmed this relationship (Table 4, Fig 5a). To compare the
strength of the relationship between serum s(P)RR level and urinary s(P)RR excretion and
eGFR, multiple regression analysis testing with urinary s(P)RR and eGFR as independent vari-
ables was performed. Only eGFR was selected as a possible independent variable; it was found
to be significantly and negatively associated with serum s(P)RR level, suggesting that the asso-
ciation between serum s(P)RR level and urinary s(P)RR excretion is confounded by renal func-
tion (Table 3b).
Study 2
The data of the study participants at enrollment are shown in Table 5. Urine qualitative tests
revealed that all participants had negative urine protein, sugar, and occult blood levels. All
these data confirmed their suitability as healthy volunteers. Although vitamin C was adminis-
tered to the participants, unexpectedly, neither urine pH nor urinary s(P)RR excretion was sig-
nificantly changed by the treatment (Fig 6), suggesting the limitation of vitamin C in reducing
urine pH. However, changes in urinary s(P)RR excretion by vitamin C treatment showed sig-
nificantly positive relationships with changes in urine pH (Fig 7, ρ = 0.8182, p = 0.0038).
Discussion
This is the first study to investigate the characteristics of urinary s(P)RR excretion; it demon-
strated two major findings regarding urinary s(P)RR excretion in humans. First, s(P)RR could
be detected in urine, and urinary s(P)RR excretion was significantly and positively correlated
with urine pH, independent of other factors in humans. Second, changes in urinary s(P)RR
excretion were positively correlated with changes in urine pH. These data support the notion
that (P)RR expression in the kidney might play a role in urine pH regulation.
In the present study, s(P)RR was detected in urine by western blotting (Fig 1), and urinary
s(P)RR concentration was measured by sandwich ELISA (Table 1). Urine pH and indices of
obesity, lipid metabolism, glucose metabolism, renal function, and inflammation were corre-
lated with urinary s(P)RR excretion (Table 2). Among the factors associated with urinary s(P)
RR excretion, urine pH showed the strongest relationship with urinary s(P)RR excretion inde-
pendent of other factors. These data suggest that urinary s(P)RR excretion is specifically associ-
ated with urine pH.
Table 3. Multiple regression analyses.
a. Multiple regression analysis with urinary soluble(pro)renin receptor excretion.
Variables β P VIF
Urine pH 0.489 <0.001 1.011
VFA -0.181 <0.001 1.011
R2 = 0.290, P < 0.0001 for entire model
b. Multiple regression analysis with serum soluble(pro)renin receptor concentration.
Variable β P
eGFR -0.214 <0.001
R2 = 0.046, P < 0.0001 for entire model
Abbreviations: VIF, variance inflation factor; VFA, visceral fat area; eGFR, estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0254688.t003
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Interestingly, there was a significant negative correlation between serum s(P)RR concentra-
tion and urinary s(P)RR excretion (Table 2). Therefore, it is unlikely that the main source of
urinary s(P)RR is blood s(P)RR filtered by the renal glomeruli, although the molecular weight
of s(P)RR is 28 kDa [18] and s(P)RR could be partially filtered by the glomeruli.
The (P)RR was identified as an accessory protein of V-ATPase, which is a multimeric pro-
tein complex with a V1 sector (eight subunits) that inherits ATPase function and a V0 sector
(six subunits) that mediates proton translocation driven by ATP cleavage [23, 24]. V-ATPase
Fig 4. Comparisons of serum s(P)RR concentration between patients with and without obesity (a) and those with
and without hypertension (b). s(P)RR, soluble (pro)renin receptor; BMI, body mass index.
https://doi.org/10.1371/journal.pone.0254688.g004
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controls the pH of the extracellular space as well as that of intracellular compartments,
depending on its actual localization (e.g., cell membranes, lysosomal membranes, membranes
of secretory granules, etc.) [25]. In the kidney, (P)RR is predominantly expressed in collecting
ducts and in the distal nephron; in addition it colocalizes with V-ATPase in type-A interca-
lated cells [26], which expels protons into the tubular lumen, thereby regulating the final uri-
nary acidification [27]. Therefore, (P)RR may play a role in the excretion of protons into the
tubular lumen via the function of V-ATPase [26]. In addition, both angiotensin II and aldoste-
rone have been shown to directly and indirectly influence transport pathways involved in acid
secretion, such as Na+/H+ exchangers and V-ATPases in different nephron segments, includ-
ing the acid-secretary type-A intercalated cells in the collecting ducts [28, 29].
In the present study, to determine the causal relationship between urinary s(P)RR excretion
and urine pH, we investigated the effects of vitamin C treatment, which may decrease urine
pH, on urinary s(P)RR excretion levels in healthy volunteers. Changes in urine pH due to vita-
min C varied among the participants, and urine pH did not change significantly in the whole
group (Fig 6); however, the change in urine pH was significantly and positively associated with




Waist circumference 0.329 <0.001
Visceral fat area 0.395 <0.001
Office BP and
Systolic BP 0.097 0.055
Diastolic BP -0.104 0.838






Uric acid 0.306 <0.001
Creatinine 0.253 <0.001
eGFR -0.224 <0.001
Corrected calcium 0.211 <0.001
Inorganic phosphorus 0.049 0.361
Albumin -0.006 0.914
Intact-PTH 0.005 0.944
Blood sugar 0.189 <0.001
Insulin 0.293 <0.001




hs CRP 0.297 <0.001
Abbreviations: BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; PTH,
parathyroid hormone; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol;
hsCRP, high-sensitivity C-reactive protein; BNP, brain natriuretic peptide.
https://doi.org/10.1371/journal.pone.0254688.t004
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Fig 5. Scattergrams showing relationship between eGFR (a), HDL-cholesterol (b), or visceral fat area (c) and
serum s(P)RR concentration. s(P)RR, soluble (pro)renin receptor; eGFR, estimated glomerular filtration rate; HDL,
high-density lipoprotein.
https://doi.org/10.1371/journal.pone.0254688.g005
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changes in urinary s(P)RR excretion levels (Fig 7). (P)RR is an accessory V-ATPase [3]. These
data prompted us to hypothesize that urinary s(P)RR excretion is increased (or decreased) due
to increased (or decreased) (P)RR expression in intercalated cells, resulting from increased (or
decreased) V-ATPase activity in these cells to compensate for the increased (or decreased)
urine pH (Fig 8), although this hypothesis needs to be investigated further. In addition, the
Table 5. Characteristics of the study subjects.
Age (y.o.) 22±2
BMI (kg/m2) 23.1±1.2
Office BP and pulse rate
Systolic BP (mmHg) 115±11
Diastolic BP (mmHg) 68±6
Pulse rate (beats/min) 59±7
Urine tests
pH 6.14 (5.76–6.78)
s(P)RR/creatinine (ng/g creatinine) 0.72 (0.25–1.26)
Blood tests
Creatinine (mg/dl) 0.85±0.06
eGFR (ml/min/1.73 m2) 96.3±7.5
Blood sugar (mg/dl) 95±4
Hemoglobin A1c (%) 5.4 (5.1–5.6)
Data are presented as mean ± standard deviation, median (interquartile range).
Abbreviations: BMI, body mass index; BP, blood pressure; s(P)RR, soluble.
(pro)renin receptor; eGFR, estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0254688.t005
Fig 6. Changes in urine pH or urinary s(P)RR excretion by vitamin C treatment. The same color was used for each of the 10 volunteers. N.S., not
significant. s(P)RR, soluble (pro)renin receptor.
https://doi.org/10.1371/journal.pone.0254688.g006
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possibility that (P)RR in the tubules or urinary s(P)RR causes increased secretion or decreased
absorption of protons in the tubules cannot be ruled out at this moment.
Serum s(P)RR concentration showed completely different features compared with urinary
s(P)RR excretion, and showed significantly positive relationships with age, BMI, WC, VFA,
urine Alb excretion, Hb, uric acid, Cre, Ca, BS, insulin, HbA1c, TG, and hsCRP, and signifi-
cantly negative relationships with urine pH, eGFR, and HDL-cholesterol (Table 4). These data
are in accordance with those of previous investigations reporting that blood s(P)RR levels are
associated with obesity [30], dyslipidemia [15], renal dysfunction [15, 21], and inflammation
[22]. These findings suggest that blood s(P)RR concentration is affected by the expression lev-
els of tissue RAS and/or tissue (P)RR in various organs. Urinary s(P)RR excretion and blood
s(P)RR concentration may reflect different physiological and/or pathophysiological conditions
in humans. Interestingly, urinary s(P)RR excretion was significantly negatively associated with
serum s(P)RR concentration (Table 2). The reason for this association is undetermined, but it
is possible that serum s(P)RR concentration is increased due to decreased renal function [15,
21] when s(P)RR production causes urinary s(P)RR excretion to be reduced. This hypothesis
needs to be tested in future studies.
Limitations
We acknowledge that this study has some limitations. First, we could not investigate the effect
of urinary alkalinization agents on volunteers for ethical reasons. The causal relationship
between urinary s(P)RR excretion and urinary proton excretion remains speculative. Second,
we could not determine the source of s(P)RR in urine in this clinical study. Third, whether
Fig 7. Scattergrams showing relationship between changes (Δ) in urine pH and urinary s(P)RR excretion by vitamin C
treatment. Closed circles, each with 10 volunteers (r = 0.878, P< 0.05), using Spearman’s rank correlation coefficient. s(P)
RR, soluble (pro)renin receptor.
https://doi.org/10.1371/journal.pone.0254688.g007
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urine s(P)RR excretion can be used as a biomarker to indicate the pathological status is unclear.
Further studies are required to clarify the significance of measuring urinary s(P)RR excretion.
Conclusions
In this study, in which the characteristics of urinary s(P)RR excretion were investigated for the
first time, s(P)RR could be detected in urine, and urinary s(P)RR excretion was shown to be
significantly positively correlated with urine pH, independent of other factors. Alterations in
urine pH caused changes in urinary s(P)RR excretion. These data suggest that (P)RR expres-
sion in the kidney might play a role in the regulation of urine pH. Further investigations are
required to determine the roles of (P)RR in the regulation of urine pH in more detail as well as








Fig 8. Hypothetical mechanism for the regulation of pH by (P)RR in kidney cells. V-ATPase, vacuolar H+-ATPase; (P)RR, (pro)renin receptor; s(P)
RR, soluble (pro)renin receptor.
https://doi.org/10.1371/journal.pone.0254688.g008
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